Adicet Bio, Inc. — Director's Dealing 2021

Mar 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2021-01-26

Reporting Person: Klickstein Lloyd (Chief Innovation Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-06	Common Stock	A	16888	$0.00	Disposed	16888	Direct
2020-10-23	Common Stock	F	4957	$0.00	Disposed	11931	Direct

Footnotes

F1: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance

F2: The amount of securities reported herein have been adjusted to reflect the 1-for-7 reverse stock split that was effected in September 2020 in connection with the merger of resTORbio, Inc. and Adicet Therapeutics, Inc., formerly known as Adicet Bio, Inc.

F3: The Reporting Person is disposing of 4,957 restricted stock units as a result of a revised tax rate for such restricted stock units